Roche’a anticipated approval of ocrelizumab will drive the company’s share of the market from <1% in 2016 to 15% by 2022, according to GBI Research The company’s report states that
Roche’a anticipated approval of ocrelizumab will drive the company’s share of the market from <1% in 2016 to 15% by 2022, according to GBI Research The company’s report states that